Related Experiment Video
Updated: May 21, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Patent foramen ovale and ischemic stroke
1Department of Neurology, University of Toulouse, Toulouse, France. larrue.v@chu-toulouse.fr
Abstract:
Patent foramen ovale (PFO) is a common finding in healthy subjects and has not been associated with increased risk of ischemic stroke in population-based cohort studies. Nevertheless, case-control studies have consistently shown an increased prevalence of PFO in cryptogenic stroke, suggesting that PFO might be a cause of stroke. The risk of stroke recurrence in patients with cryptogenic stroke and PFO is low under aspirin therapy but may be substantially higher in patients with an associated atrial septal aneurysm (ASA). The mechanisms of stroke associated with PFO or ASA are uncertain. Paradoxical embolism through the PFO is rarely documented. The optimal treatment for secondary prevention in patients with cryptogenic stroke and PFO is still uncertain and debated. A randomized controlled trial failed to demonstrate the superiority of transcatheter PFO closure over medical therapy. Whether anticoagulation is superior to aspirin should be tested in a randomized controlled trial.
Insights
Patent foramen ovale (PFO) is common and usually benign. However, it may increase stroke risk, especially with atrial septal aneurysm (ASA), necessitating further research into optimal secondary prevention strategies.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Patent foramen ovale (PFO) is a frequent finding in healthy individuals, typically not linked to ischemic stroke risk in population studies.
- Conversely, case-control studies indicate a higher prevalence of PFO in cryptogenic stroke patients, suggesting a potential causal role.
- The association between PFO, atrial septal aneurysm (ASA), and stroke mechanisms remains unclear, with paradoxical embolism being rarely documented.
Purpose of the Study:
- To review the current understanding of patent foramen ovale (PFO) and atrial septal aneurysm (ASA) in the context of cryptogenic stroke.
- To discuss the uncertainties surrounding the mechanisms of stroke associated with PFO/ASA.
- To evaluate the current and debated treatment strategies for secondary prevention in patients with cryptogenic stroke and PFO.
Main Methods:
- Literature review and synthesis of findings from population-based cohort studies, case-control studies, and randomized controlled trials.
- Analysis of the evidence regarding stroke risk, recurrence, and potential mechanisms related to PFO and ASA.
- Evaluation of existing and proposed secondary prevention treatments, including medical therapy and device closure.
Main Results:
- While PFO is common and not typically associated with stroke risk, its prevalence is higher in cryptogenic stroke cases.
- Stroke recurrence risk in PFO patients with cryptogenic stroke is low with aspirin but may increase with ASA.
- A randomized trial did not show transcatheter PFO closure to be superior to medical therapy.
Conclusions:
- The role of PFO in cryptogenic stroke requires further investigation, particularly concerning its interaction with ASA.
- Optimal secondary prevention for cryptogenic stroke patients with PFO remains uncertain and debated.
- Future randomized controlled trials are needed to compare anticoagulation with aspirin and to further elucidate PFO closure efficacy.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Hemorrhagic Stroke l: Introduction
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
